Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:EBR) ) just unveiled an announcement.
EBR Systems, Inc. has received final approval from the U.S. Centers for Medicare & Medicaid Services (CMS) for Transitional Pass-Through (TPT) reimbursement for its WiSE CRT System, effective October 1, 2025. This approval, alongside the New Technology Add-On Payment (NTAP) for inpatient use, provides comprehensive reimbursement coverage, facilitating hospital adoption and expanding patient access to this innovative heart failure therapy.
The most recent analyst rating on (AU:EBR) stock is a Buy with a A$2.48 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.
More about EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
Silicon Valley-based EBR Systems, Inc. is a company focused on advancing cardiac rhythm disease treatment through its proprietary Wireless Stimulation Endocardially (WiSE) technology. This technology eliminates the need for traditional cardiac pacing leads, addressing complications and reliability issues. The WiSE CRT System is the world’s only wireless endocardial pacing system for the heart’s left ventricle, aiming to provide superior and anatomically correct cardiac pacing.
Average Trading Volume: 707,235
Technical Sentiment Signal: Buy
See more data about EBR stock on TipRanks’ Stock Analysis page.